Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + imprime PGG + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of three agents: **atezolizumab (a PD-L1 checkpoint inhibitor monoclonal antibody, developed by Genentech/Roche)**; **imprime PGG (a novel immunomodulatory beta-glucan, developed by Biothera Pharmaceuticals)**; and **bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor A, developed by Genentech/Roche)**. Atezolizumab blocks the PD-L1 immune checkpoint pathway to restore the anti-tumor activity of T cells. Imprime PGG is an immunomodulatory beta-glucan that primes innate immune cells (especially neutrophils and monocytes) to foster an enhanced anti-tumor immune response. Bevacizumab inhibits tumor angiogenesis by binding VEGF-A, preventing new blood vessel formation essential for tumor growth. This combination is being investigated in clinical trials primarily targeting solid tumors, including hepatocellular carcinoma and various advanced cancers, in the context of immunotherapy and anti-angiogenic strategies.
- Other names
- atezolizumab + imprime PGG + bevacizumab
02
Targets
PRR (Pattern recognition receptors)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on atezolizumab + imprime PGG + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + imprime PGG + bevacizumab.